

Research Compliance Activity and Turn-Around-Time (TAT) Summary Report
Fiscal Year 2020 (7/1/2019 to 6/30/2020)

TAT calculated from submission date to date of approval. TAT not calculated for continuing reviews.

Institutional Biosafety Committee (IBC) - IUPUI								
	Q1 TAT		Q2 TAT		Q3 TAT		Q4 TAT	
	Mean	Median	Mean	Median	Mean	Median	Mean	Median
Full Board								
New Studies - Full Board (to review)	18.5	30.0	27.0	24.0	29.7	27.5	26.0	23.0
New Studies - Full Board (to approval)	37.1	40.0	34.9	43.0	35.3	35.0	41.6	44.0
Exempt								
New Studies - Exempt (to determination)	12.5	19.0	16.8	18.0	26.3	48.8	11.5	8.5
Amendments								
Amendments - Minor	4.9	2.0	5.5	2.0	4.7	2.0	4.3	1.0
Amendments - Major	34.4	36.5	27.8	26.0	23.6	14.0	29.3	21.0

Area Activities/Throughput (T)	Q1 (Jul-Sep)			Q2 (Oct-Dec)			Q3 (Jan-Mar)			Q4 (Apr-Jun)		
	Received	Completed	Throughput/ % Backlogged									
New Studies - Full Board	16	8	-8 (50.0%)	18	19	1 (5.6%)	15	17	2 (13.3%)	21	14	-7 (33.3%)
New Studies - Exempt	13	11	-2 (15.4%)	4	6	2 (50.0%)	10	9	-1 (10.0%)	11	6	-5 (45.5%)
Amendments - Minor	172	159	-13 (7.6%)	132	145	13 (9.9%)	138	139	1 (0.7%)	85	80	-5 (5.9%)
Amendments - Major	22	23	1 (4.5%)	25	20	-5 (20.0%)	26	29	3 (11.5%)	26	18	-8 (30.8%)
Continuing Reviews	86	82	-4 (4.7%)	88	89	1 (1.1%)	95	98	3 (3.2%)	76	71	-5 (6.6%)
TOTAL	309	283	-26 (8.4%)	267	279	12 (-4.5%)	284	292	8 (-2.8%)	219	189	-30 (13.7%)

Area Training Activities	Q1 (Jul-Sep)	Q2 (Oct-Dec)	Q3 (Jan-Mar)	Q4 (Apr-Jun)	FY TOTALS
Presentations (# of events)	2	0	0	1	3

Reportable Events/Activities	Q1 (Jul-Sep)	Q2 (Oct-Dec)	Q3 (Jan-Mar)	Q4 (Apr-Jun)	FY TOTALS
Immediate OBA Report	0	1	0	0	1
30 Day OBA Report	0	0	0	0	0
Lab Accident/Injury/Exposure	0	1	0	0	1

Reporting Agency: NIH Office of Biotechnology Activities (OBA)